What is Leerink Partnrs' Estimate for Icon FY2025 Earnings?

Key Points

• Leerink Partnrs has lowered its FY2025 earnings per share estimate for Icon Plc to $12.63, down from a previous forecast of $12.67, while consensus estimates stand at $13.38.
• Icon's most recent quarterly earnings report showed a net margin of 9.82% and revenue of $2.02 billion, exceeding expectations of $1.98 billion but down 4.8% year-over-year.
• Analyst ratings for Icon are favorable, with two analysts assigning a Strong Buy rating, while the average price target is $217.33.

Icon Plc (NASDAQ:ICLR - Free Report) - Investment analysts at Leerink Partnrs decreased their FY2025 earnings per share estimates for shares of Icon in a report issued on Wednesday, October 8th. Leerink Partnrs analyst M. Cherny now forecasts that the medical research company will post earnings per share of $12.63 for the year, down from their previous estimate of $12.67. The consensus estimate for Icon's current full-year earnings is $13.38 per share. Leerink Partnrs also issued estimates for Icon's FY2026 earnings at $13.43 EPS, FY2027 earnings at $15.28 EPS and FY2028 earnings at $16.94 EPS.

Icon (NASDAQ:ICLR - Get Free Report) last issued its quarterly earnings data on Wednesday, July 23rd. The medical research company reported $3.26 earnings per share for the quarter, beating the consensus estimate of $3.18 by $0.08. Icon had a return on equity of 10.95% and a net margin of 9.82%.The business had revenue of $2.02 billion for the quarter, compared to analysts' expectations of $1.98 billion. During the same period last year, the business earned $3.75 EPS. The business's revenue was down 4.8% on a year-over-year basis. Icon has set its FY 2025 guidance at 13.000-14.000 EPS.

Other equities analysts have also recently issued reports about the company. Rothschild Redb upgraded Icon from a "hold" rating to a "strong-buy" rating in a research note on Wednesday, September 3rd. Truist Financial raised their target price on Icon from $187.00 to $234.00 and gave the company a "buy" rating in a research report on Friday, July 25th. Rothschild & Co Redburn raised Icon from a "neutral" rating to a "buy" rating and raised their target price for the company from $184.00 to $236.00 in a research report on Wednesday, September 3rd. Citigroup reaffirmed a "neutral" rating and set a $200.00 target price (down from $225.00) on shares of Icon in a research report on Thursday, August 21st. Finally, UBS Group raised their target price on Icon from $170.00 to $240.00 and gave the company a "buy" rating in a research report on Friday, July 25th. Two research analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating and nine have issued a Hold rating to the company. According to MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus price target of $217.33.

Icon Price Performance

Shares of NASDAQ:ICLR opened at $186.48 on Thursday. The company has a current ratio of 1.29, a quick ratio of 1.29 and a debt-to-equity ratio of 0.35. The stock's fifty day simple moving average is $173.85 and its two-hundred day simple moving average is $156.97. Icon has a 1-year low of $125.10 and a 1-year high of $303.69. The stock has a market cap of $15.06 billion, a PE ratio of 19.19, a price-to-earnings-growth ratio of 2.77 and a beta of 1.23.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in the stock. Artisan Partners Limited Partnership grew its holdings in Icon by 67.4% during the 2nd quarter. Artisan Partners Limited Partnership now owns 7,184,870 shares of the medical research company's stock valued at $1,045,039,000 after buying an additional 2,893,946 shares in the last quarter. Massachusetts Financial Services Co. MA grew its holdings in Icon by 21.0% during the 2nd quarter. Massachusetts Financial Services Co. MA now owns 3,752,008 shares of the medical research company's stock valued at $545,730,000 after buying an additional 650,379 shares in the last quarter. Invesco Ltd. grew its holdings in Icon by 3.3% during the 2nd quarter. Invesco Ltd. now owns 3,085,993 shares of the medical research company's stock valued at $448,858,000 after buying an additional 98,032 shares in the last quarter. Ninety One UK Ltd boosted its position in shares of Icon by 2.6% during the 2nd quarter. Ninety One UK Ltd now owns 2,993,652 shares of the medical research company's stock valued at $435,427,000 after acquiring an additional 75,465 shares during the last quarter. Finally, Ruane Cunniff & Goldfarb L.P. boosted its position in shares of Icon by 36.2% during the 2nd quarter. Ruane Cunniff & Goldfarb L.P. now owns 1,708,183 shares of the medical research company's stock valued at $248,455,000 after acquiring an additional 453,833 shares during the last quarter. Hedge funds and other institutional investors own 95.61% of the company's stock.

Icon Company Profile

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.